Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.06), $0.27 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $713.4 million versus the consensus estimate of $694.92 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.03-3.09 billion, versus the consensus of $3.06 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Laser Photonics regains NASDAQ compliance after filing quarterly report
• Circle board member resigns after nearly 13 years of service